补肾活血法联合硼替佐米治疗多发性骨髓瘤的临床效果

Clinical efficacy of tonifying kidney and activating blood method combined with bortezomib in the treatment of multiple myeloma

目的探讨补肾活血法联合硼替佐米治疗多发性骨髓瘤的临床疗效。方法选取广州市中西医结合医院2017年4月至2020年4月收治的60例多发性骨髓瘤患者作为研究对象,根据治疗方案的不同分为联合组30例与对照组30例。对照组采取硼替佐米化疗方案治疗,联合组在此基础上采取补肾活血法治疗,比较两组患者临床治疗效果。结果联合组总有效率(90.00%)明显高于对照组(66.67%),差异有统计学意义(P<0.05)。治疗前,联合组骨痛VAS评分与对照组比较,差异无统计学意义(P>0.05);经过治疗,两组VAS评分较治疗前下降,但联合组低于对照组,差异有统计学意义(P<0.05)。联合组不良反应总发生率为23.33%,对照组为26.67%,差异无统计学意义(P>0.05)。结论补肾活血法联合硼替佐米治疗多发性骨髓瘤整体效果较优,有利于缓解患者临床症状,值得推广。

Objective To investigate the clinical efficacy of tonifying kidney and activating blood method combined with bortezomib in the treatment of multiple myeloma.Methods Sixty patients with multiple myeloma admitted to Guangzhou Hospital of Integrated Traditional and West Medicine from April 2017 to April 2020 were selected as the study subjects,and were divided into the combination group and the control group according to different treatment protocols,with 30 cases in each group.The control group was treated with bortezomib chemotherapy protocol,while the combination group was treated with the tonifying kidney and activating blood method on this basis,and the actual efficacy of the two groups were compared.Results The total effective rate of the combined group(90.00%)was significantly higher than that of the control group(66.67%),and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the score of Visual Analogue Scale/Score(VAS)of bone pain between the combination group and the control group(P>0.05).After treatment,the VAS scores decreased in both groups,but the score was lower in the combination group,with statistically significant difference(P<0.05).The total incidence of adverse reactions(ARs)was 23.33%in the combination group and 26.67%in the control group,There was no statistically significant difference between the two groups(P>0.05).Conclusion The combination of tonifying kidney and activating blood method with bortezomib exerts better clinical efficacy in the treatment of multiple myeloma,which can further alleviate the clinical symptoms of patients,and is worthy of promotion and application.